Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer.
In conclusion, high circulating IL-6 was associated with short OS in most studies in GI cancer patients. Whether inhibition of IL-6 would decrease GI cancer symptoms and increase quality of life is unknown.
PMID: 30038723 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Bile | Bladder Cancer | Cancer | Cancer & Oncology | Colorectal Cancer | Gallbladder Cancer | Gastric (Stomach) Cancer | Gastroenterology | General Practices | Pancreas | Pancreatic Cancer | Primary Care | Study